BEIJING SUN-NOVO PHARMACEUTICAL RESEARCH CO., LTD.

Beijing Sun-Novo Pharmaceutical Research Co., Ltd.

688621

CNE100005139

Biotechnology & Medical Research

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-04-28 pm EDT			5-day change	1st Jan Change
57.69 ^CNY	+1.51%		-2.88%	-17.29%

Apr. 25	Beijing Sun-Novo Pharmaceutical Research Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Feb. 26	Beijing Sun-Novo Pharmaceutical Research Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Beijing Sun-Novo Pharmaceutical Research Co., Ltd.(SHSE:688621) added to Shanghai Stock Exchange Composite Index

June 21, 2022 at 12:00 am EDT

Beijing Sun-Novo Pharmaceutical Research Co., Ltd has been added to Shanghai Stock Exchange Composite Index

Latest news about Beijing Sun-Novo Pharmaceutical Research Co., Ltd.

Beijing Sun-Novo Pharmaceutical Research Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 25	CI
Beijing Sun-Novo Pharmaceutical Research Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 26	CI
Beijing Sun-Novo Pharmaceutical Research Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-30	CI
Beijing Sun-Novo Pharmaceutical Research Co., Ltd.(XSSC:688621) added to S&P Global BMI Index	23-09-18	CI
Beijing Sun-Novo Pharmaceutical Research Co., Ltd. cancelled the acquisition of Beijing Langyan Life Technology Holdings Co., Ltd. from a group of shareholders.	23-09-03	CI
Beijing Sun-Novo Pharmaceutical Research Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-28	CI
Sun-Novo Pharma Gets License to Produce Kaneka’s Transdermal Patches	23-05-16	MT
Beijing Sun-Novo Pharmaceutical Research Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-28	CI
Sun-Novo Pharma Unit Gets Drug Regulator's Certification for Desmopressin Injection	23-04-13	MT
Sun-Novo Pharma Unit to Set Up 10 Million Joint Venture With Midea Pharma	23-04-12	MT
Beijing Sun-Novo Pharmaceutical Research Co., Ltd. announced that it expects to receive CNY 1 billion in funding	23-04-10	CI
Sun-Novo Pharma Logs 49.8% Jump in 2022 Profit	23-02-10	MT
Beijing Sun-Novo Pharmaceutical Research Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-09	CI
Sun-Novo Pharmaceutical Purchases Azilsartan Tablets’ Marketing Rights For $5 Million	22-11-23	MT
Beijing Sun-Novo Gets Regulatory Approval in China For Anti-Dermatitis Cream	22-11-22	MT
Beijing Sun-Novo Pharmaceutical Research Co., Ltd. announced that it expects to receive CNY 1 billion in funding	22-11-06	CI
Beijing Sun-Novo Pharmaceutical Research Co., Ltd. agreed to acquire Beijing Langyan Life Technology Holdings Co., Ltd. from Li Qian, Ganzhou Langyi Investment Center (Limited Partnership), Liu Yujing and other shareholders.	22-10-24	CI
Beijing Sun-Novo Pharmaceutical Research Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-24	CI
Beijing Sun-Novo Pharmaceutical Research Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-09	CI
Beijing Sun-Novo Pharmaceutical Research Co., Ltd.(SHSE:688621) added to Shanghai Stock Exchange Composite Index	22-06-21	CI
Beijing Sun-Novo Pharmaceutical Research Co., Ltd.(SHSE:688621) added to Shanghai Stock Exchange A Share Index	22-06-21	CI
Beijing Sun-Novo Pharmaceutical Research Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-28	CI
Nanjing Heron Pharmaceutical Science and Technology Co.,LTD announced that it expects to receive CNY 20.000024 million in funding from Beijing Sun-Novo Pharmaceutical Research Co., Ltd.	22-01-24	CI
Beijing Sun-Novo Pharmaceutical Research Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	22-01-20	CI
Beijing Sun-Novo Pharmaceutical Research Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	21-10-27	CI

Chart Beijing Sun-Novo Pharmaceutical Research Co., Ltd.

Duration

Period

Chart Beijing Sun-Novo Pharmaceutical Research Co., Ltd.

More charts

Beijing Sun Novo Pharmaceutical Research Co Ltd is a China-based company that provides research and development outsourcing services for pharmaceutical companies. The Company's main businesses include comprehensive research and development services in generic drug development, consistency evaluation and innovative drug development. Its services mainly include pharmaceutical research, clinical trials and biological analysis. Pharmaceutical research services include raw materials and preparation process research, quality standards and stability research, etc. Clinical trial services include phase I-IV clinical trial research, Bioequivalency (BE) test research. Biological analysis services include the use of mass spectrometry analysis platform, immunoassay platform, cell analysis platform, molecular biology analysis platform for method development, method validation, biological sample detection research, etc. The Company mainly conducts its businesses in the domestic market.

Sector

Biotechnology & Medical Research

Calendar

2024-08-15 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Beijing Sun-Novo Pharmaceutical Research Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

57.69

Average target price

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
BEIJING SUN-NOVO PHARMACEUTICAL RESEARCH CO., LTD.	-17.29%	878M
IQVIA HOLDINGS INC.	+1.77%	42.75B
LONZA GROUP AG	+47.70%	41.61B
MODERNA, INC.	+12.24%	41.34B
CELLTRION, INC.	-8.83%	26.59B
ICON PUBLIC LIMITED COMPANY	+7.44%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-23.01%	18.12B
MEDPACE HOLDINGS, INC.	+30.56%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.82%	11.76B
UNITED THERAPEUTICS CORPORATION	+8.35%	11B

Other Biotechnology & Medical Research